Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Data demonstrated that Risvodetinib was well tolerated up to 7 days of daily dosing with no serious adverse events in healthy volunteers or worsening of symptoms in participants taking anti-PD.
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.